Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|20/08/2019||Prominent biotech investor leads investment in Race||Download|
|13/08/2019||Race announces additional US Patent for Bisantrene||Download|
|07/08/2019||Appendix 3Y-Dr William Garner||Download|
|30/07/2019||Appendix 4C - quarterly||Download|
|25/07/2019||First patient treated in Bisantrene trial in Israel||Download|
|12/07/2019||Appendix 3Y-Dr William Garner||Download|
|12/07/2019||Change in substantial holding||Download|